Publications
477
Citations
24,019
Est. group size
~12
Recurring co-author estimate
Active years
29
Publishing since 1998
Maryam Fouladi's research focuses on pediatric brain tumors, particularly the design and analysis of clinical trials testing new drugs and treatment strategies for children with tumors such as low-grade glioma, high-grade glioma, medulloblastoma, ependymoma, and diffuse intrinsic pontine glioma (DIPG). Much of the work is conducted through multi-institution research consortia (such as the Pediatric Brain Tumor Consortium and Children's Oncology Group) and covers targeted therapies (like selumetinib and lenalidomide), immunotherapy (immune checkpoint inhibitors such as pembrolizumab), and molecular/genetic classification of tumors. This research aims to improve survival and reduce treatment-related harm in children and young adults with central nervous system tumors.
Publication output has fluctuated over the last decade, with a notable spike in 2023 followed by a decline in 2024-2025, though the 5-year average remains steady at roughly 30 papers per year.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Response to “Reporting of outcomes of young children with embryonal CNS tumors after radiotherapy-avoiding strategies: Comments on ACNS0334”
Neuro-Oncology · 2026
- Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children’s Oncology Group
Neuro-Oncology · 2025
- A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4
Neuro-Oncology · 2025
- IDH mutant high-grade gliomas
Frontiers in Molecular Neuroscience · 2025
- IMMU-79. An Updated Analysis of PD1 and Immune Pathway Activity in Malignant Pediatric Central Nervous System (CNS) Tumors: A Pediatric Brain Tumor Consortium (PBTC) Study, PBTC-N13
Neuro-Oncology · 2025
- IMMU-05. Outcome of patients with hypermutant or recurrent high-grade gliomas treated with pembrolizumab, an immune checkpoint inhibitor: a Pediatric Brain Tumor Consortium study (PBTC045).
Neuro-Oncology Pediatrics · 2025
- ETMR-12. Rare Brain Tumor Consortia (RBTC) case series: Insights into primary brainstem ETMRs, a rare and aggressive tumor of childhood
Neuro-Oncology Pediatrics · 2025
- Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions
Neuro-Oncology · 2024
- Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors
JAMA Oncology · 2024
- Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201
Journal of Clinical Oncology · 2024
- CTIM-06. OUTCOME OF PATIENTS WITH RECURRENT MEDULLOBLASTOMA AND EPENDYMOMA TREATED WITH PEMBROLIZUMAB, AN IMMUNE CHECKPOINT INHIBITOR: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY (PBTC045)
Neuro-Oncology · 2024
- EPEN-29. IS THE OUTCOME OF SUPRATENTORIAL EPENDYMOMA WITH ZFTA FUSION REALLY POOR?
Neuro-Oncology · 2024
- LGG-05. REPORT ON PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC)-029B, A PROSPECTIVE PHASE 2 CLINICAL TRIAL OF SELUMETINIB IN TREATING YOUNG PATIENTS WITH RECURRENT/PROGRESSIVE LOW-GRADE GLIOMA: NEW RESULTS ON STRATA 2, 5, AND 6 WITH UPDATED LONG-TERM SURVIVAL OUTCOMES ON STRATA 1, 3, AND 4
Neuro-Oncology · 2024
- GCT-06. THE OUTCOMES OF PATIENTS WITH DISSEMINATED GERMINOMA TREATED ON ACNS0232: A REPORT FROM THE CHILDREN’S ONCOLOGY REPORT
Neuro-Oncology · 2024
- IMMU-08. OUTCOME OF PATIENTS WITH RECURRENT MEDULLOBLASTOMA AND EPENDYMOMA TREATED WITH PEMBROLIZUMAB, AN IMMUNE CHECKPOINT INHIBITOR: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY (PBTC045)
Neuro-Oncology · 2024
- Neuro-Oncology×146
- Journal of Clinical Oncology×23
- Journal of Neuro-Oncology×10
- International Journal of Radiation Oncology*Biology*Physics×9
- Pediatric Blood & Cancer×8
- Daniel R. Boué
Medicine · The Ohio State University
- Margot Lazow
Medicine · The Ohio State University
- Sara Khan
Medicine · The Ohio State University
- Jonathan L. Finlay
Medicine · The Ohio State University
- Ralph Salloum
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile